hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review

Table 1 Characteristics of the identified studies

Ref.	Year of publication	Country	Inclusion period	No. of patients	Study design	Follow-up median (95%CI), mo
Spratlin et al[9]	2004	Canada	1998–2002	21	RS	NR
Giovannetti et al[10]	2006	Italy	2001–2004	1021	RS	11.2 (0.4–32.1)
Farrell et al[12]	2009	United States	1998–2002	91	Post hoc2	NR
Maréchal et al[3]	2009	Belgium	2000–2003	45	RS	21.9 (3.3–107.4)
Fujita et al[8]	2010	Japan	1992–2007	70	RS	15.7 (0.5–114)
Maréchal et al[1]	2012	Belgium	1996–2009	234	RS	55.7 (46.4–61.2)
Kawada et al[2]	2012	Japan	2002–2007	63	RS	31
Morinaga et al[21]	2012	Japan	2006–2008	27	RS	NR
Murata et al[22]	2012	Japan	2005–2010	93	RS	15 (3.5–57.2)
Nakagawa et al[23]	2012	Japan	2002–2011	109	RS	39.7 (2–122)
				Total: 855

¹n = 81 with complete hENT1;

²Post hoc analysis of randomized controlled trial. NR: Not reported; RS: Retrospective.